Can Zydus saroglitazar compete with Iqirvo and Livdelzi in the US PBC market?
Zydus saroglitazar shows 60.7% US biochemical response in PBC as its November 27 FDA decision approaches. Examine the Phase 3 evidence.
Pharma & Biotech